Figure 6.

Inhibition of Ang II synthesis ameliorates allergic inflammation. (A–H) Naive mice were i.n. challenged with papain (Pap, 20 µg/d), followed by daily i.p. injection with captopril (Cap, 10 mg/kg) or vehicle solution for 5 d; PBS was used as control. (A) Experimental strategy. (B–D) Abundance and absolute numbers (B), cytokine production (C), and proliferation (D) of ILC2s in lung were determined by flow cytometry. (E) Concentration of IL-5 and IL-13 in BALF. (F) Abundance and counts of eosinophils (Eos). (G) Concentration of Ang II in BALF. (H) H&E staining and quantitated histological scoring (scale bar, 100 µm). (I and J) Naive mice were i.p. injected with telmisartan (Tel; 10 mg/kg), PD123319 (PD; 10 mg/kg), or PBS after papain administration. (I) Experimental strategy. (J) Representative H&E staining of lung sections (scale bar, 100 µm). (K–M) Naive mice i.n. administered telmisartan and captopril after papain challenge 1 h. (K) Flow plots and abundances of eosinophils. (L) IL-5 and IL-13 concentration in BALF. (M) Proliferation and cytokine production of ILC2s. All data are representative of two independent experiments; n = 4 or 5/group. Graphical data show mean ± SEM; unpaired t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Vel, vehicle.